179 related articles for article (PubMed ID: 26264279)
1. Antiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression.
Shang Z; Li Y; Zhang M; Tian J; Han R; Shyr CR; Messing E; Yeh S; Niu Y; Chang C
Mol Cancer Ther; 2015 Nov; 14(11):2586-94. PubMed ID: 26264279
[TBL] [Abstract][Full Text] [Related]
2. Targeting estrogen/estrogen receptor alpha enhances Bacillus Calmette-Guérin efficacy in bladder cancer.
Shang Z; Li Y; Hsu I; Zhang M; Tian J; Wen S; Han R; Messing EM; Chang C; Niu Y; Yeh S
Oncotarget; 2016 May; 7(19):27325-35. PubMed ID: 27092883
[TBL] [Abstract][Full Text] [Related]
3. ASC-J9® increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF-κB survival signals.
Huang CP; Chen J; Chen CC; Liu G; Zhang Y; Messing E; Yeh S; Chang C
J Exp Clin Cancer Res; 2019 Jun; 38(1):275. PubMed ID: 31234917
[TBL] [Abstract][Full Text] [Related]
4. Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth.
Kawahara T; Ide H; Kashiwagi E; El-Shishtawy KA; Li Y; Reis LO; Zheng Y; Miyamoto H
Urol Oncol; 2016 Oct; 34(10):432.e15-23. PubMed ID: 27330033
[TBL] [Abstract][Full Text] [Related]
5. ASC-J9
Lin W; Luo J; Sun Y; Lin C; Li G; Niu Y; Chang C
Cancer Lett; 2018 Jul; 425():21-30. PubMed ID: 29425687
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor (AR) degradation enhancer ASC-J9
Cheng MA; Chou FJ; Wang K; Yang R; Ding J; Zhang Q; Li G; Yeh S; Xu D; Chang C
Cancer Lett; 2018 Mar; 417():182-191. PubMed ID: 29203251
[TBL] [Abstract][Full Text] [Related]
7. Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression.
Chou FJ; Chen Y; Chen D; Niu Y; Li G; Keng P; Yeh S; Chang C
EBioMedicine; 2019 Feb; 40():504-516. PubMed ID: 30692044
[TBL] [Abstract][Full Text] [Related]
8. Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9® led to increase docetaxel sensitivity via suppressing the p21 expression.
Luo J; Tian J; Chou F; Lin C; Xing EZ; Zuo L; Niu Y; Yeh S; Chang C
Cancer Lett; 2019 Mar; 444():35-44. PubMed ID: 30248372
[TBL] [Abstract][Full Text] [Related]
9. ASC-J9(®), and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals.
Wen S; Tian J; Niu Y; Li L; Yeh S; Chang C
Cancer Lett; 2016 Jul; 376(2):377-86. PubMed ID: 27045473
[TBL] [Abstract][Full Text] [Related]
10. ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors.
Yamashita S; Lai KP; Chuang KL; Xu D; Miyamoto H; Tochigi T; Pang ST; Li L; Arai Y; Kung HJ; Yeh S; Chang C
Neoplasia; 2012 Jan; 14(1):74-83. PubMed ID: 22355276
[TBL] [Abstract][Full Text] [Related]
11. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.
Lai KP; Huang CK; Chang YJ; Chung CY; Yamashita S; Li L; Lee SO; Yeh S; Chang C
Am J Pathol; 2013 Feb; 182(2):460-73. PubMed ID: 23219429
[TBL] [Abstract][Full Text] [Related]
12. Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors.
Kamat AM; Tharakan ST; Sung B; Aggarwal BB
Cancer Res; 2009 Dec; 69(23):8958-66. PubMed ID: 19903839
[TBL] [Abstract][Full Text] [Related]
13. A review of the effects and molecular mechanisms of dimethylcurcumin (ASC-J9) on androgen receptor-related diseases.
Hu H; Zhou H; Xu D
Chem Biol Drug Des; 2021 Apr; 97(4):821-835. PubMed ID: 33277796
[TBL] [Abstract][Full Text] [Related]
14. Targeting androgen receptor with ASC-J9 attenuates cardiac injury and dysfunction in experimental autoimmune myocarditis by reducing M1-like macrophage.
Ma W; Wang Y; Lu S; Yan L; Hu F; Wang Z
Biochem Biophys Res Commun; 2017 Apr; 485(4):746-752. PubMed ID: 28246012
[TBL] [Abstract][Full Text] [Related]
15. ASC-J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling.
Tian H; Chou FJ; Tian J; Zhang Y; You B; Huang CP; Yeh S; Niu Y; Chang C
J Exp Clin Cancer Res; 2021 Jan; 40(1):3. PubMed ID: 33390173
[TBL] [Abstract][Full Text] [Related]
16. Androgen Receptor Signaling Reduces the Efficacy of Bacillus Calmette-Guérin Therapy for Bladder Cancer via Modulating Rab27b-Induced Exocytosis.
Mizushima T; Jiang G; Kawahara T; Li P; Han B; Inoue S; Ide H; Kato I; Jalalizadeh M; Miyagi E; Fukuda M; Reis LO; Miyamoto H
Mol Cancer Ther; 2020 Sep; 19(9):1930-1942. PubMed ID: 32737155
[TBL] [Abstract][Full Text] [Related]
17. Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells.
Wen S; Niu Y; Lee SO; Yeh S; Shang Z; Gao H; Li Y; Chou F; Chang C
Mol Carcinog; 2016 Dec; 55(12):2278-2290. PubMed ID: 26894509
[TBL] [Abstract][Full Text] [Related]
18. Androgen dependent regulation of bacillus Calmette-Guerin induced interleukin-6 expression in human transitional carcinoma cell lines.
Chen F; Langenstroer P; Zhang G; Iwamoto Y; See W
J Urol; 2003 Nov; 170(5):2009-13. PubMed ID: 14532843
[TBL] [Abstract][Full Text] [Related]
19. Promotion of bladder cancer development and progression by androgen receptor signals.
Miyamoto H; Yang Z; Chen YT; Ishiguro H; Uemura H; Kubota Y; Nagashima Y; Chang YJ; Hu YC; Tsai MY; Yeh S; Messing EM; Chang C
J Natl Cancer Inst; 2007 Apr; 99(7):558-68. PubMed ID: 17406000
[TBL] [Abstract][Full Text] [Related]
20. Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor.
Hsu JW; Hsu I; Xu D; Miyamoto H; Liang L; Wu XR; Shyr CR; Chang C
Am J Pathol; 2013 May; 182(5):1811-20. PubMed ID: 23499463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
